Woodline Partners’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $21.7M | Buy |
1,920,664
+303,195
| +19% | +$3.43M | 0.11% | 266 |
|
|
2025
Q1 | $18.7M | Buy |
1,617,469
+329,068
| +26% | +$3.8M | 0.12% | 241 |
|
|
2024
Q4 | $10.9M | Buy |
1,288,401
+680,148
| +112% | +$5.76M | 0.07% | 321 |
|
|
2024
Q3 | $7.04M | Buy |
608,253
+457,791
| +304% | +$5.3M | 0.06% | 344 |
|
|
2024
Q2 | $1.77M | Hold |
150,462
| – | – | 0.02% | 428 |
|
|
2024
Q1 | $1.78M | Sell |
150,462
-196,401
| -57% | -$2.33M | 0.02% | 428 |
|
|
2023
Q4 | $4.25M | Buy |
+346,863
| New | +$4.25M | 0.05% | 330 |
|
|
2023
Q3 | – | Sell |
-108,358
| Closed | -$975K | – | 673 |
|
|
2023
Q2 | $975K | Buy |
+108,358
| New | +$975K | 0.01% | 483 |
|
|
2023
Q1 | – | Sell |
-593,810
| Closed | -$4.01M | – | 707 |
|
|
2022
Q4 | $4.01M | Sell |
593,810
-159,071
| -21% | -$1.08M | 0.05% | 350 |
|
|
2022
Q3 | $10.9M | Sell |
752,881
-334,002
| -31% | -$4.85M | 0.15% | 189 |
|
|
2022
Q2 | $10.7M | Buy |
1,086,883
+589,869
| +119% | +$5.8M | 0.16% | 165 |
|
|
2022
Q1 | $7.33M | Buy |
497,014
+358,276
| +258% | +$5.28M | 0.12% | 206 |
|
|
2021
Q4 | $1.84M | Buy |
138,738
+9,387
| +7% | +$124K | 0.03% | 434 |
|
|
2021
Q3 | $2.26M | Buy |
129,351
+27,645
| +27% | +$482K | 0.04% | 393 |
|
|
2021
Q2 | $2.44M | Sell |
101,706
-122,353
| -55% | -$2.93M | 0.05% | 327 |
|
|
2021
Q1 | $5.76M | Buy |
+224,059
| New | +$5.76M | 0.13% | 179 |
|